Hospitalist Continuity Doesn't Appear to Greatly Affect AEs

This article originally appeared here.
Share this content:
Hospitalist Continuity Doesn't Appear to Greatly Affect AEs
Hospitalist Continuity Doesn't Appear to Greatly Affect AEs

FRIDAY, March 13, 2015 (HealthDay News) -- Measures of hospitalist physician continuity do not show a consistent or significant association with the incidence of adverse events (AEs), according to research published in the March issue of the Journal of Hospital Medicine.

Kevin J. O'Leary, M.D., of the Northwestern University Feinberg School of Medicine in Chicago, and colleagues conducted a retrospective observational study to examine the association between hospital physician continuity and the incidence of AEs. The analysis included data from 474 hospitalizations on a nonteaching service in a large academic hospital.

The researchers found that, in unadjusted models, each 1-unit increase in the Number of Physicians Index (NPI), representing less continuity, was significantly associated with the incidence of one or more AEs (odds ratio, 1.75; P < 0.001). In these models, the Usual Provider of Care (UPC) index was not associated with the incidence of AEs. In all adjusted models, no significant associations of NPI or UPC with incidence of AEs were found. In these models, the direction of the effect of discontinuity on the incidence of AEs also was inconsistent.

"Our findings are somewhat surprising because of the high value placed on continuity of care and patient safety concerns related to handoffs," the authors write. "We speculate that hospitalist continuity is only one of many team factors that may influence patient safety, and that prior efforts within our institution may have reduced our ability to detect an association."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »